 This study has identified a new mechanism by which cancer cells evade the immune system in renal cell carcinoma, RCC, and suggests that targeting this mechanism could improve the effectiveness of immunotherapies. The researchers found that a protein called EHBP1L1 is overexpressed in RCC and is responsible for blocking the body's natural ability to fight off the cancer. When EHBP1L1 was blocked or reduced, the cancer cells were more susceptible to immunotherapy treatments. This finding could lead to improved treatment options for patients with RCC. This article was authored by Ehue Pan, Guan Nan Xu, Liang Min Fu, and others.